Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

2 results

  • 20 - Parkinson’s Disease
  • from Section 6
  • Edited by Bernard Ravina, Jeffrey Cummings, Michael McDermott, R. Michael Poole
  • Book: Clinical Trials in Neurology
  • Published online: 05 May 2012
  • Print publication: 12 April 2012, pp 215-226
  • View extract

    Summary

    Clinical trials in Parkinson's disease (PD) have focused in two major areas: treatments designed to alleviate signs and symptoms in the short run, and treatments designed to modify the long-term progression of the illness. In clinical trials of short-term improvement with early PD patients the most common primary outcome measure is the Unified Parkinson's Disease Rating Scale (UPDRS). Motoric dysfunction, loss of ambulatory capability, cognitive impairment, mood disruption, and autonomic dysfunction all eventually contribute to potentially severe disability in individuals with advanced PD. Trials are just emerging that focus on the development of overall disability in PD, rather than measuring impairments in any particular domain such as motor function or cognitive impairment. Multiple trial designs have been proposed and used in studies to assess disease modification in PD. Several particular safety concerns have emerged in the context of PD clinical trials.